S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway

Repligen (RGEN) Stock Price, News & Analysis

$195.52
+1.53 (+0.79%)
(As of 03/1/2024 ET)
Today's Range
$190.80
$196.34
50-Day Range
$170.78
$208.42
52-Week Range
$110.45
$211.13
Volume
526,144 shs
Average Volume
559,795 shs
Market Capitalization
$10.90 billion
P/E Ratio
271.56
Dividend Yield
N/A
Price Target
$196.70

Repligen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
0.6% Upside
$196.70 Price Target
Short Interest
Healthy
10.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.23mentions of Repligen in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$1.06 M Sold Last Quarter
Proj. Earnings Growth
45.21%
From $1.46 to $2.12 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.58 out of 5 stars

Medical Sector

275th out of 951 stocks

Biological Products, Except Diagnostic Industry

42nd out of 155 stocks


RGEN stock logo

About Repligen Stock (NASDAQ:RGEN)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

RGEN Stock Price History

RGEN Stock News Headlines

Repligen Corp RGEN
Repligen Corp COO James Bylund Sells 4,373 Shares
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
James Bylund Sells 4,373 Shares of Repligen Co. (NASDAQ:RGEN) Stock
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Repligen (NASDAQ:RGEN) PT Raised to $207.00
Decoding Repligen Corp (RGEN): A Strategic SWOT Insight
Repligen Stock (NASDAQ:RGEN), Short Interest Report
Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates
Repligen Q4 2023 Earnings Preview
Repligen Corp.
See More Headlines
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/03/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
1,783
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$196.70
High Stock Price Target
$220.00
Low Stock Price Target
$165.00
Potential Upside/Downside
+0.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$41.58 million
Pretax Margin
10.04%

Debt

Sales & Book Value

Annual Sales
$638.76 million
Cash Flow
$3.05 per share
Book Value
$35.35 per share

Miscellaneous

Free Float
55,158,000
Market Cap
$10.90 billion
Optionable
Optionable
Beta
1.03

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report














RGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Repligen stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGEN shares.
View RGEN analyst ratings
or view top-rated stocks.

What is Repligen's stock price target for 2024?

9 Wall Street analysts have issued 1-year price objectives for Repligen's shares. Their RGEN share price targets range from $165.00 to $220.00. On average, they predict the company's stock price to reach $196.70 in the next year. This suggests a possible upside of 0.6% from the stock's current price.
View analysts price targets for RGEN
or view top-rated stocks among Wall Street analysts.

How have RGEN shares performed in 2024?

Repligen's stock was trading at $179.80 at the start of the year. Since then, RGEN stock has increased by 8.7% and is now trading at $195.52.
View the best growth stocks for 2024 here
.

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our RGEN earnings forecast
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) issued its quarterly earnings data on Wednesday, February, 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The biotechnology company had revenue of $155.74 million for the quarter, compared to analyst estimates of $155.38 million. Repligen had a net margin of 6.51% and a trailing twelve-month return on equity of 5.00%. Repligen's quarterly revenue was down 16.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.68 EPS.

What guidance has Repligen issued on next quarter's earnings?

Repligen updated its FY24 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of $1.42-1.49 for the period, compared to the consensus earnings per share estimate of $1.77. The company issued revenue guidance of $620-650 million, compared to the consensus revenue estimate of $660.67 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Who are Repligen's major shareholders?

Repligen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.10%), Price T Rowe Associates Inc. MD (7.18%), Brown Capital Management LLC (2.73%), Artisan Partners Limited Partnership (2.73%), Sands Capital Management LLC (2.68%) and Impax Asset Management Group plc (1.64%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends
.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Repligen have any subsidiaries?
The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More
This page (NASDAQ:RGEN) was last updated on 3/3/2024 by MarketBeat.com Staff